1. Hahner S, Ross RJ, Arlt W, Bancos I, Burger-Stritt S, Torpy DJ, et al. Adrenal insufficiency. Nat Rev Dis Primers. 2021; 7:19.
2. Husebye ES, Pearce SH, Krone NP, Kampe O. Adrenal insufficiency. Lancet. 2021; 397:613–29.
3. Barthel A, Benker G, Berens K, Diederich S, Manfras B, Gruber M, et al. An update on Addison’s disease. Exp Clin Endocrinol Diabetes. 2019; 127:165–75.
4. Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016; 101:364–89.
5. Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, et al. Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016; 101:3888–921.
6. Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. BMJ. 2021; 374:n1380.
7. Papierska L, Rabijewski M. Delay in diagnosis of adrenal insufficiency is a frequent cause of adrenal crisis. Int J Endocrinol. 2013; 2013:482370.
8. Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999; 341:1013–20.
9. Diederich S, Franzen NF, Bahr V, Oelkers W. Severe hyponatremia due to hypopituitarism with adrenal insufficiency: report on 28 cases. Eur J Endocrinol. 2003; 148:609–17.
10. Garrahy A, Thompson CJ. Hyponatremia and glucocorticoid deficiency. Front Horm Res. 2019; 52:80–92.
11. Benner BJ, Alsma J, Feelders RA. Hyponatraemia and hyperpigmentation in primary adrenal insufficiency. BMJ Case Rep. 2019; 12:e227200.
12. Mohamed F, Raal FJ. Hyperpigmentation from Addison’s disease. N Engl J Med. 2021; 384:1752.
13. Abdel-Malek ZA, Knittel J, Kadekaro AL, Swope VB, Starner R. The melanocortin 1 receptor and the UV response of human melanocytes: a shift in paradigm. Photochem Photobiol. 2008; 84:501–8.
14. Grossman AB. Clinical review: the diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab. 2010; 95:4855–63.
15. Kumar R, Carr P, Wassif W. Diagnostic performance of morning serum cortisol as an alternative to short synacthen test for the assessment of adrenal reserve; a retrospective study. Postgrad Med J. 2022; 98:113–8.
16. Charoensri S, Chailurkit L, Muntham D, Bunnag P. Serum dehydroepiandrosterone sulfate in assessing the integrity of the hypothalamic-pituitary-adrenal axis. J Clin Transl Endocrinol. 2017; 7:42–6.
17. Nasrallah MP, Arafah BM. The value of dehydroepiandrosterone sulfate measurements in the assessment of adrenal function. J Clin Endocrinol Metab. 2003; 88:5293–8.
18. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet. 1991; 337:582–3.
19. Brossaud J, Gatta B, Tabarin A, Corcuff JB. Different methods to estimate serum free cortisol: a comparison during cortisol tetracosactide testing. Clin Chem Lab Med. 2015; 53:1367–73.
20. Javorsky BR, Raff H, Carroll TB, Algeciras-Schimnich A, Singh RJ, Colon-Franco JM, et al. New cutoffs for the biochemical diagnosis of adrenal insufficiency after ACTH stimulation using specific cortisol assays. J Endocr Soc. 2021; 5:bvab022.
21. Ospina NS, Al Nofal A, Bancos I, Javed A, Benkhadra K, Kapoor E, et al. ACTH stimulation tests for the diagnosis of adrenal insufficiency: systematic review and meta-analysis. J Clin Endocrinol Metab. 2016; 101:427–34.
22. Schmidt IL, Lahner H, Mann K, Petersenn S. Diagnosis of adrenal insufficiency: evaluation of the corticotropin-releasing hormone test and Basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. J Clin Endocrinol Metab. 2003; 88:4193–8.
23. Krasowski MD, Drees D, Morris CS, Maakestad J, Blau JL, Ekins S. Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction. BMC Clin Pathol. 2014; 14:33.
24. Erturk E, Jaffe CA, Barkan AL. Evaluation of the integrity of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia test. J Clin Endocrinol Metab. 1998; 83:2350–4.
25. Giordano R, Picu A, Bonelli L, Balbo M, Berardelli R, Marinazzo E, et al. Hypothalamus-pituitary-adrenal axis evaluation in patients with hypothalamo-pituitary disorders: comparison of different provocative tests. Clin Endocrinol (Oxf). 2008; 68:935–41.
26. Steiner H, Bahr V, Exner P, Oelkers PW. Pituitary function tests: comparison of ACTH and 11-deoxy-cortisol responses in the metyrapone test and with the insulin hypoglycemia test. Exp Clin Endocrinol. 1994; 102:33–8.
27. Berneis K, Staub JJ, Gessler A, Meier C, Girard J, Muller B. Combined stimulation of adrenocorticotropin and compound-S by single dose metyrapone test as an outpatient procedure to assess hypothalamic-pituitary-adrenal function. J Clin Endocrinol Metab. 2002; 87:5470–5.
28. Ach T, Yosra H, Jihen M, Abdelkarim Asma B, Maha K, Molka C, et al. Cortisol cut-points for the glucagon stimulation test in the evaluation of hypothalamic pituitary adrenal axis. Endocr J. 2018; 65:935–42.
29. Hamrahian AH, Yuen KC, Gordon MB, Pulaski-Liebert KJ, Bena J, Biller BM. Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter study. Pituitary. 2016; 19:332–41.
30. Cegla J, Jones B, Seyani L, Papadoulou D, Wynne K, Martin NM, et al. Comparison of the overnight metyrapone and glucagon stimulation tests in the assessment of secondary hypoadrenalism. Clin Endocrinol (Oxf). 2013; 78:738–42.
31. Kim YJ, Kim JH, Hong AR, Park KS, Kim SW, Shin CS, et al. Stimulated salivary cortisol as a noninvasive diagnostic tool for adrenal insufficiency. Endocrinol Metab (Seoul). 2020; 35:628–35.
32. Langelaan ML, Kisters JM, Oosterwerff MM, Boer AK. Salivary cortisol in the diagnosis of adrenal insufficiency: cost efficient and patient friendly. Endocr Connect. 2018; 7:560–6.
33. Mak IY, Au Yeung BY, Ng YW, Choi CH, Iu HY, Shek CC, et al. Salivary cortisol and cortisone after low-dose corticotropin stimulation in the diagnosis of adrenal insufficiency. J Endocr Soc. 2017; 1:96–108.
34. Debono M, Caunt S, Elder C, Fearnside J, Lewis J, Keevil B, et al. Real world evidence supports waking salivary cortisone as a screening test for adrenal insufficiency. Clin Endocrinol (Oxf). 2023; 99:517–24.
35. Elder CJ, Vilela R, Johnson TN, Taylor RN, Kemp EH, Keevil BG, et al. Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test. J Clin Endocrinol Metab. 2020; 105:dgaa323.
36. Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, et al. Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab. 2009; 94:1548–54.
37. Esteban NV, Yergey AL. Cortisol production rates measured by liquid chromatography/mass spectrometry. Steroids. 1990; 55:152–8.
38. Kumar R, Wassif WS. Adrenal insufficiency. J Clin Pathol. 2022; 75:435–42.
39. Quinkler M, Ekman B, Marelli C, Uddin S, Zelissen P, Murray RD, et al. Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency. Endocr Connect. 2017; 6:1–8.
40. Frey KR, Kienitz T, Schulz J, Ventz M, Zopf K, Quinkler M. Prednisolone is associated with a worse bone mineral density in primary adrenal insufficiency. Endocr Connect. 2018; 7:811–8.
41. Rushworth RL, Torpy DJ, Falhammar H. Adrenal crisis. N Engl J Med. 2019; 381:852–61.
42. Werumeus Buning J, Touw DJ, Brummelman P, Dullaart RP, van den Berg G, van der Klauw MM, et al. Pharmacokinetics of oral hydrocortisone: results and implications from a randomized controlled trial. Metabolism. 2017; 71:7–16.
43. Arafah BM. Hypothalamic pituitary adrenal function during critical illness: limitations of current assessment methods. J Clin Endocrinol Metab. 2006; 91:3725–45.
44. Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab. 2012; 97:473–81.
45. Isidori AM, Venneri MA, Graziadio C, Simeoli C, Fiore D, Hasenmajer V, et al. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018; 6:173–85.
46. Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engstrom BE, et al. Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study. Eur J Endocrinol. 2017; 176:715–25.
47. Quinkler M, Miodini Nilsen R, Zopf K, Ventz M, Oksnes M. Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur J Endocrinol. 2015; 172:619–26.
48. Whitaker M, Debono M, Huatan H, Merke D, Arlt W, Ross RJ. An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. Clin Endocrinol (Oxf). 2014; 80:554–61.
49. Mallappa A, Sinaii N, Kumar P, Whitaker MJ, Daley LA, Digweed D, et al. A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2015; 100:1137–45.
50. Jones CM, Mallappa A, Reisch N, Nikolaou N, Krone N, Hughes BA, et al. Modified-release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2017; 102:1797–806.
51. Oksnes M, Bjornsdottir S, Isaksson M, Methlie P, Carlsen S, Nilsen RM, et al. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of Addison’s disease: a randomized clinical trial. J Clin Endocrinol Metab. 2014; 99:1665–74.
52. Hindmarsh PC. The child with difficult to control congenital adrenal hyperplasia: is there a place for continuous subcutaneous hydrocortisone therapy. Clin Endocrinol (Oxf). 2014; 81:15–8.
53. Mallappa A, Nella AA, Sinaii N, Rao H, Gounden V, Perritt AF, et al. Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 2018; 89:399–407.
54. Sævik AB, Akerman AK, Methlie P, Quinkler M, Jorgensen AP, Hoybye C, et al. Residual corticosteroid production in autoimmune Addison disease. J Clin Endocrinol Metab. 2020; 105:2430–41.
55. Esposito D, Pasquali D, Johannsson G. Primary adrenal insufficiency: managing mineralocorticoid replacement therapy. J Clin Endocrinol Metab. 2018; 103:376–87.
56. Williams GH, Cain JP, Dluhy RG, Underwood RH. Studies of the control of plasma aldosterone concentration in normal man. I. Response to posture, acute and chronic volume depletion, and sodium loading. J Clin Invest. 1972; 51:1731–42.
57. Smith SJ, MacGregor GA, Markandu ND, Bayliss J, Banks RA, Prentice MG, et al. Evidence that patients with Addison’s disease are undertreated with fludrocortisone. Lancet. 1984; 1:11–4.
58. Inder WJ, Meyer C, Hunt PJ. Management of hypertension and heart failure in patients with Addison’s disease. Clin Endocrinol (Oxf). 2015; 82:789–92.
59. Alkatib AA, Cosma M, Elamin MB, Erickson D, Swiglo BA, Erwin PJ, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009; 94:3676–81.
60. Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99:3489–510.